ENMD 2076

Drug Profile

ENMD 2076

Alternative Names: ENMD-2076; ENMD-981693; MKC-1693

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Miikana Therapeutics
  • Developer CASI Pharmaceuticals
  • Class Antineoplastics; Piperazines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Aurora kinase A inhibitors; Fms-like tyrosine kinase 3 inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Multiple myeloma; Hepatocellular carcinoma; Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Hepatocellular carcinoma; Ovarian cancer; Soft tissue sarcoma
  • Phase I Acute myeloid leukaemia; Cancer; Haematological malignancies; Multiple myeloma

Most Recent Events

  • 19 Jul 2016 Phase-I clinical trials in Hepatocellular carcinoma in China (PO) before July 2016
  • 19 Jul 2016 Phase-I clinical trials in Soft tissue sarcoma in China (PO) before July 2016
  • 12 May 2016 China Food and Drug Administration approves clinical trial application for phase II trial in Hepatocellular carcinoma (fibrolamellar carcinoma)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top